A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062 ·Status: COMPLETED ·Phase: PHASE3

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

NCT04756934 ·Status: UNKNOWN ·Phase: PHASE1

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

NCT01777776 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

HL-085 in NRAS-mutated Advanced Melanoma

NCT05217303 ·Status: COMPLETED ·Phase: PHASE2

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

NCT01436656 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

NCT02738489 ·Status: COMPLETED ·Phase: PHASE1

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

NCT01153763 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085 ·Status: COMPLETED ·Phase: PHASE2

AMT-253 in Patients With Advanced Solid Tumours

NCT06209580 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

NCT02768207 ·Status: COMPLETED ·Phase: PHASE2

Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma

NCT00068211 ·Status: COMPLETED ·Phase: PHASE2

CP-675,206 In Patients With Advanced Melanoma

NCT00086489 ·Status: COMPLETED ·Phase: PHASE2

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

NCT02159066 ·Status: COMPLETED ·Phase: PHASE2

Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

NCT05070221 ·Status: UNKNOWN ·Phase: PHASE1

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

NCT07280832 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

NCT02723006 ·Status: TERMINATED ·Phase: PHASE1

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

NCT01894672 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

NCT04768881 ·Status: TERMINATED ·Phase: PHASE2

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

NCT06424626 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

NCT01266967 ·Status: COMPLETED ·Phase: PHASE2

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

NCT01928940 ·Status: COMPLETED ·Phase: PHASE2

Phase II, 2nd Line Melanoma - RAND Monotherapy

NCT00612664 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

NCT01227889 ·Status: COMPLETED ·Phase: PHASE3

Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis

NCT05068453 ·Status: UNKNOWN ·Phase: PHASE1

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

NCT02036086 ·Status: UNKNOWN ·Phase: PHASE2